Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Untitled design(220)

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.

The company’s lead drug candidate, MM120 ODT (lysergide D-tartrate or LSD), is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics that acts as a partial agonist at human serotonin-2A (5-HT2A) receptors.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.